University Health Network
🇨🇦Canada
Study to Assess the Safety and Effects of Porphysome Nanoparticles for Imaging in Gynaecological Cancers
Phase 1
Not yet recruiting
- Conditions
- Gynecological Cancers
- Interventions
- Drug: PORPHYSOMESDrug: 64Cu-PORPHYSOMES
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 24
- Registration Number
- NCT06977126
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Buccal Fat for Transoral Robotic Lateral Oropharyngectomy Defects to and Postoperative Pain
Phase 2
Not yet recruiting
- Conditions
- Tonsil NeoplasmOropharynx NeoplasmTransoral Robotic Surgery
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 40
- Registration Number
- NCT06965738
- Locations
- 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
Deep Brain Stimulation of the Pedunculopontine Nucleus for Alzheimer's Disease
Not Applicable
Recruiting
- Conditions
- Alzheimer Disease
- First Posted Date
- 2025-04-20
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 6
- Registration Number
- NCT06936124
- Locations
- 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
The Safety and Feasibility of Radiofrequency Ablation to Treat Low-risk Thyroid Cancer
Not Applicable
Recruiting
- Conditions
- Thyroid NoduleThyroid Cancer
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 40
- Registration Number
- NCT06929650
- Locations
- 🇨🇦
University Health Network, Toronto, Ontario, Canada
Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer
Phase 2
Not yet recruiting
- Conditions
- Castrate Resistance Prostate CancerOligoProgressive Metastatic Disease
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 75
- Registration Number
- NCT06927635
Effect of Hi-OxSR for the Treatment of Post COVID Condition (RECLAIM-HiOxSR)
Not Applicable
Not yet recruiting
- Conditions
- Long COVIDPost COVID-19 ConditionPost Acute Sequelae of COVID-19
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 120
- Registration Number
- NCT06928506
Testing Zanubrutinib and Tislelizumab as Well as Standard of Care for the Treatment of Patients With Progressive Lymphoma Post Anti-CD19 CAR-T Cell Therapy
Phase 2
Not yet recruiting
- Conditions
- Progressive Lymphoma Post Anti-CD19 CAR-T Cell Therapy
- Interventions
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 76
- Registration Number
- NCT06919705
- Locations
- 🇨🇦
610 University Health Network, Toronto, Ontario, Canada
Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus
Phase 2
Not yet recruiting
- Conditions
- Kidney Transplant Recipient
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 74
- Registration Number
- NCT06913023
- Locations
- 🇨🇦
St. Paul's Hospital, Vancouver, British Columbia, Canada
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada
Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer
Phase 2
Not yet recruiting
- Conditions
- Castration Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 35
- Registration Number
- NCT06836726
- Locations
- 🇨🇦
Princess Margaret Cancer Center, Toronto, Ontario, Canada
Peri-procedural Management of Direct Oral Anticoagulants for Central VENOus Catheters in CAncer Patients With Venous Thromboembolism or Atrial Fibrillation Pilot Study
Not Applicable
Not yet recruiting
- Conditions
- Anticoagulant-induced BleedingCentral Venous CatheterDirect Oral AnticoagulantCancerPeriprocedural Complication
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 10
- Registration Number
- NCT06887270
- Locations
- 🇨🇦
University Health Network, Toronto, Ontario, Canada
© Copyright 2025. All Rights Reserved by MedPath